GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
16.00
+0.07 (0.44%)
At close: Mar 9, 2026, 4:00 PM EDT
15.98
-0.02 (-0.12%)
After-hours: Mar 9, 2026, 4:10 PM EDT
GH Research Market Cap
GH Research has a market cap or net worth of $992.47 million as of March 9, 2026. Its market cap has increased by 14.29% in one year.
Market Cap
992.47M
Enterprise Value
684.67M
1-Year Change
14.29%
Ranking
Category
Stock Price
$16.00
Market Cap Chart
Since the IPO on June 25, 2021, GH Research's market cap has increased from $808.33M to $992.47M, an increase of 22.78%. That is a compound annual growth rate of 4.46%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 988.13M | 25.43% |
| Dec 31, 2025 | 787.77M | 116.30% |
| Dec 31, 2024 | 364.20M | 20.71% |
| Dec 29, 2023 | 301.72M | -40.33% |
| Dec 30, 2022 | 505.64M | -58.34% |
| Dec 31, 2021 | 1.21B | 50.14% |
| Jun 25, 2021 | 808.33M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Pharming Group | 1.06B |
| AbCellera Biologics | 1.05B |
| ArriVent BioPharma | 1.04B |
| Inhibrx Biosciences | 1.01B |
| Xeris Biopharma Holdings | 1.00B |
| UroGen Pharma | 996.04M |
| Compass Therapeutics | 992.28M |
| Aktis Oncology | 987.94M |